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Targeted deep sequencing of
CD341 cells from peripheral
blood can reproduce bone
marrow molecular profile in
myelodysplastic syndromes
To the Editor:
Myelodysplastic syndromes (MDS) are clonal stem cell diseases of the
bone marrow (BM). Acquired somatic mutations account for MDS
development and constitute important diagnostic and prognostic
markers. Currently, BM aspirates are used for genetic analysis in MDS
patients. In this study, we aimed to investigate whether the high sensi-
tivity of targeted deep sequencing (TDS) allows the detection of
genetic alterations in peripheral blood (PB) of MDS patients. PB can be
obtained by minimally invasive venipuncture and would be ideal for a
comprehensive sequential monitoring of MDS over time.
This study includes 48 patients which were analyzed by TDS using
either a hybridization probe-based (Supporting Information Table S1)
or an amplicon-based TDS sequencing panel (Supporting Information
Table S2). We analyzed bone marrow cells (BMC), PB mononuclear
cells (PB-MC), and immunomagnetically enriched CD341 PB cells (PB-
CD34) (Supporting Information Figure S1).
To identify molecular markers of clinical relevance, we screened
genes previously reported to be frequently mutated in MDS and other
myeloid malignancies.1,2 The somatic origin of the variants was validated
by comparison of the concurrent samples (BMC, PB-CD34, and PB-MC)
with a paired germline sample, peripheral CD31 cells (PB-CD3).
TDS allowed the detection of potential MDS-related aberrations in
41/48 patients (85%). This was a significant increase of informative cases
compared to the results of the classical cytogenetic approaches, chromo-
some banding analysis (CBA), and fluorescence in situ hybridization
(FISH), which yielded an altered karyotype in 17/48 (35%) cases. The
application of single nucleotide polymorphism arrays (SNP-A) allowed the
detection of aberrations (submicroscopic copy number changes or copy
number neutral loss of heterozygosity) in seven additional patients with
normal karyotype (Supporting Information Tables S3 and S4).
Overall, the combined application of classical cytogenetics, molecular
karyotyping, and TDS identified genetic alterations in 43/48 (90%) patients.
TDS allowed the identification of 105 mutations in 24 genes. The
highest mutation frequencies were observed for TET2 (n513, 27%),
SF3B1 (n510, 21%), SRSF2 (n510, 21%), ASXL1 (n57, 16%), EZH2
(n56, 13%), ZRSR2 (n56, 13%), RUNX1 (n55, 10%), U2AF1 (n55,
10%), and TP53 (n54, 8%) (Supporting Information Figure S2).
As previously reported we detected an increased number of genetic
lesions in high-risk WHO subtypes (Supporting Information Figure S3A)
and found a correlation between the average number of genetic aberra-
tions and the IPSS-R prognostic risk score (Supporting Information Fig-
ure S3B).1,2 Interestingly, low risk patients displayed an increased
number of somatic mutations compared to the number of lesions
detected by CBA or SNP-A. This observation is consistent with data
published by Tefferi et al. indicating that TDS can significantly improve
prognostication and risk stratification in lower risk MDS patients.3
Comparison of the TDS results from BM and PB revealed that
TDS allows detection of somatic mutations also in PB samples (Figure
1A). For non-enriched PB, this was previously shown,4 while in the cur-
rent study we have added PB-CD34. We were able to detect 93/105
mutations (89%) in all sample types (BMC, PB-CD34, and PB-MC) (Sup-
porting Information Table S5). In BMC, we found 100/105 (95%), in
PB-CD34 102/105 (97%), and in PB-MC 95/105 (90%). Thus, enrich-
ment of CD341 cells increased the detection rate of mutations in PB.
Besides the qualitative detection of somatic mutations, TDS allows
the quantification of the mutation burden by the variant allele fre-
quency (VAF) and the estimation of the tumor clone size.
The measured VAF values were significantly lower for PB-MC
(median525.1%) compared to BMC (median536.4%, P5 .002)
(Figure 1B,C). Decreased VAF values in PB were also reported by
Mohamedali et al.4 However, the differences were not statistically sig-
nificant. The significant deviation that we observed potentially resulted
from a more stringent removal of SNPs in our dataset due to the analy-
sis of the germline sample (CD31).
The decreased VAF values measured in PB-MC are consistent
with the lower detection rates in PB-MC samples since low frequency
mutations drop below the detection limit of the applied TDS analysis
(5%) in PB (Supporting Information Table S5 and Figure S4). Including
mutations below the detection threshold of 5% VAF allowed the recov-
ery of nearly all mutations (102/105) in BMC, PB-CD34 as well as PB-
MC and resulted in the discovery of two additional mutations that
might have clinical relevance (data not shown). The currently ongoing
optimization of NGS sample preparation kits will facilitate the detection
of mutations with VAF values below 5%, improving the reliability of
the method especially for challenging sample types such as PB.
In order to overcome the limitations of PB in the quantification of
somatic mutations, we additionally tested CD341, which were immu-
nomagnetically enriched from PB. Although the yield and purity of
CD341 cells depends on physiological conditions such as disease state
or therapy and technical challenges, we were able to obtain sufficient
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DNA from PB-CD34 for TDS in all cases (see Supporting Information
Methods). Regarding the total dataset, we did not observe differences
in the VAF distribution between BMC (median536.4%) and PB-CD34
(median534.7%, P5 .954) (Figure 1B,D).
A similar experimental setup was previously used by Braulke et al.5
The authors applied FISH analysis on CD341 cells from PB and BM and
observed a slight but not significant difference. It is likely that we did not
observe such differences due to the analysis of unselected BMC.
It is noteworthy that we also observed apparent variations of the
VAF values in PB-MC compared to BMC or PB-CD34 for some muta-
tions. However, in most cases only individual mutations of the patient
were affected and in just two cases the differences would have
resulted in a changed assessment of the clonal hierarchy that was esti-
mated by the VAF (Supporting Information Table S5).
Taken together, our data indicate that TDS allows the adequate
detection of somatic mutations from BM, circulating CD341 cells and
PB-MC. However, the malignant cell population is less abundant in the
PB-MC fraction and therefore the detection and especially the quantifi-
cation of clonal somatic mutations is more challenging in this sample
type. Immunomagnetic enrichment of circulating CD341 cells from PB
allowed to obtain TDS data that are well comparable to the results
from BMC. Therefore, we recommend to use CD341 cells from PB in




FIGURE 1 Recovery ofmutations in BM and PB samples by TDS. A,Most mutationswere detectable in samples fromBM and PB. Overall, 105muta-
tions were found. A total of 93 aberrationswere recovered in BMC, CD341 cells enriched from PB (PB-CD34) as well as inmononuclear PB cells (PB-
MC). Tenmutationswere not recovered in PB-MC samples. Fivemutations were not detected in BMC samples. Three additional aberrationswere
exclusively found in BMC. Inconsistent recovery was apparentmostly formutationswith lowVAF values below 5%. Numbers in parentheses were
obtained by including variants detected at<5%VAF values after reanalysis. B, Distribution of themeasured VAFs for the samples fromBMC, PB-CD34,
andPB-MC. The VAF values of the second and third quartiles are between 15% and45% for all sample types. Themedian VAF (black horizontal lines in
the boxes) for BMC and PB-CD34 is 36.4% and 34.7%, respectively. The value for PB-MC is significantly lower (25.1%, P5 .001 and P5 .002). P-values
were determined according toMann–Whitney–Wilcoxon test. C,D,Mutual correlation of theVAF for the individual mutations identified in BMC, PB-
CD34, and PB-MC.Dots denote the VAF of individual mutations, bisecting lines aremarked in black, and regression lines are shown as dashed red lines.
R denotes the SpearmanCorrelation Coefficient. P denotes the Spearman Correlation P-value. C, Values of PB-MCare lower compared to themeasured
VAF fromBMC. Individual mutations with values above 50% indicate potential copy number variations. D, In contrast, concordance between the VAF of
BMC andPB-CD34 is apparent asmost values cluster near the bisecting line
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Hemoglobin response to
ferric citrate in patients with
nondialysis-dependent chronic
kidney disease and iron
deficiency anemia
To the Editor:
Anemia is a common complication in patients with chronic kidney dis-
ease (CKD) and often occurs due to iron deficiency. Causes of iron
deficiency in CKD include upregulation of hepcidin (a peptide hormone
that reduces iron transport across enterocytes) leading to decreased
dietary iron absorption, impaired iron release from body stores associ-
ated with heightened inflammation, and gastrointestinal blood loss. All
result in insufficient bone marrow iron availability and inefficient eryth-
ropoiesis, leading to iron deficiency anemia.1
Recent clinical practice guidelines from Kidney Disease: Improving
Global Outcomes recommend using oral or intravenous iron before
erythropoietin-stimulating agents for the treatment of iron deficiency
anemia in patients with nondialysis-dependent (NDD)-CKD.1 Oral iron
preparations are typically ineffective and/or poorly tolerated due to
gastrointestinal side effects.1 Intravenous iron is used infrequently in
nephrology offices as it requires intravenous infusion in a monitored
setting with facilities for resuscitation because of risks of serious
adverse drug events, including hypersensitivity reactions.1
In a randomized placebo-controlled trial of ferric citrate in 234
patients with NDD-CKD and iron deficiency anemia,2 ferric citrate-
treated patients were significantly more likely to achieve a 1.0 g/dL
increase in hemoglobin (52.1% vs. 19.1% with placebo; P< .001) during
the 16-week randomized phase; the least-squares mean (LSM) relative
change in hemoglobin was 0.84 g/dL (95% confidence interval [CI],
0.58-1.10).2
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